{
    "pmcid": "9481167",
    "qa_pairs": {
        "What is the primary target of the biosynthetic proteins developed in the study for antiviral activity against SARS-CoV-2?": [
            "The receptor binding domain (RBD) of the spike protein",
            "The nucleocapsid protein of the virus",
            "The membrane protein of the virus",
            "The RNA polymerase of the virus"
        ],
        "What method was used to enhance the neutralization potency of \u03b1Reps in the study?": [
            "Engineering multivalent forms by linking \u03b1Reps or creating trimeric forms",
            "Increasing the concentration of monomeric \u03b1Reps",
            "Using chemical modifications to increase binding affinity",
            "Combining \u03b1Reps with traditional antibodies"
        ],
        "What structural feature of \u03b1Reps contributes to their enhanced stability compared to traditional nanobodies?": [
            "A rigid alpha-helicoidal HEAT-like scaffold",
            "A flexible beta-sheet framework",
            "A single-chain variable fragment (scFv) structure",
            "A disulfide-rich loop configuration"
        ],
        "What was the observed effect of nasal instillation of F9-C2 in the hamster model?": [
            "Reduced viral replication and inflammation in the nasal cavity",
            "Increased viral load in the lungs",
            "No significant change in viral replication",
            "Enhanced immune response without affecting viral replication"
        ],
        "Which \u03b1Rep was identified to bind a site overlapping with the ACE2 binding site on the SARS-CoV-2 spike protein?": [
            "F9",
            "C2",
            "A1",
            "B7"
        ]
    }
}